The Silent Crisis in Arunachal Pradesh's Pharmacies: How Weak Enforcement Endangers Public Health

Across the mist-laden hills and remote valleys of Arunachal Pradesh, a quiet but dangerous crisis is unfolding—not in the form of a new disease, but in the unregulated distribution of medicines. While the state grapples with geographic isolation, limited healthcare infrastructure, and a fragile supply chain, a parallel challenge has emerged: the widespread availability of counterfeit, substandard, and improperly stored drugs. Recent enforcement actions by the Directorate of Health Services (DHS) have exposed systemic vulnerabilities in the state’s pharmaceutical oversight, revealing a regulatory gap that threatens the health of over 1.6 million residents. This is not merely a local issue—it is a microcosm of a larger national problem, where weak enforcement in India’s peripheral states enables a shadow market of dangerous medicines.

The stakes could not be higher. According to the World Health Organization (WHO), up to 10.5% of all medicines in low- and middle-income countries are counterfeit or substandard. In India, where the pharmaceutical industry is valued at over $50 billion, the regulatory framework is robust on paper but often fails in practice—especially in remote regions like the Northeast. Arunachal Pradesh, with its scattered population and challenging terrain, presents a perfect storm for regulatory failure. But the recent licensing drive is more than a crackdown—it is a clarion call for systemic reform in how India protects its most vulnerable citizens from medical harm.

The Hidden Epidemic: Why Counterfeit Drugs Thrive in Arunachal Pradesh

The problem of counterfeit and substandard drugs is not new, but its persistence in Arunachal Pradesh reflects deeper structural issues. Unlike urban centers where pharmacies are licensed and audited regularly, many outlets in the state operate under minimal oversight. A 2023 report by the All India Drug Action Network (AIDAN) found that 34% of medicine shops in Arunachal Pradesh lacked proper licensing, and 18% were found storing drugs at temperatures outside recommended ranges—conditions that accelerate degradation and render medications ineffective or toxic.

Several factors contribute to this crisis. First, geographic remoteness limits the reach of regulatory bodies. The state spans over 83,743 square kilometers, much of it accessible only by treacherous roads or air. The Directorate of Health Services relies on a skeletal enforcement team, often stretched thin across 16 districts. Second, cultural practices intersect with modern healthcare. Traditional healers and local practitioners frequently dispense allopathic medicines without proper training, blurring the line between legitimate and illicit distribution. Third, supply chain inefficiencies create shortages of essential drugs, prompting black-market imports from neighboring states like Assam and Nagaland—where regulatory standards may be similarly lax.

The consequences are dire. Counterfeit antibiotics, for instance, can lead to treatment failure, prolonged illness, and the rise of drug-resistant infections. A study published in the Journal of Clinical Epidemiology found that 23% of patients in Northeast India who believed they were taking genuine antibiotics were actually consuming counterfeit versions. In Arunachal Pradesh, this has translated into higher incidences of typhoid, malaria, and even tuberculosis not responding to standard treatment regimens.

From Paper to Practice: The Role of Licensing in Public Health Security

The recent licensing drive by the Directorate of Health Services is a critical intervention, but its success hinges on more than just issuing or revoking licenses. It represents a shift from passive regulation to active enforcement—a move long overdue in a state where pharmacies have historically operated in a legal gray zone. Under the Drugs and Cosmetics Act, 1940, all medicine outlets must be licensed by the State Drug Control Authority. Yet, compliance has been inconsistent. The DHS’s current initiative, which began in early 2024, aims to audit every registered pharmacy and unregistered medicine shop, with a focus on cold chain compliance, storage conditions, and proper record-keeping.

One of the most promising aspects of this drive is its integration with the Ayushman Bharat Digital Mission (ABDM). By linking pharmacy licenses to a digital registry, authorities can track the movement of drugs from manufacturer to patient—a crucial step in curbing illegal trade. However, challenges remain. Many rural pharmacies lack internet connectivity, and literacy levels among shop owners are often low, making digital compliance difficult. To address this, the DHS has partnered with local NGOs to conduct awareness campaigns in languages like Nyishi, Adi, and Galo, translating regulatory jargon into accessible information.

Another innovative measure is the introduction of QR code verification for high-risk drugs such as insulin, vaccines, and antibiotics. Patients can now scan a code on the packaging to verify authenticity through a government portal. Early data shows a 12% reduction in reported adverse drug reactions in districts where this system has been piloted. This suggests that transparency, not just enforcement, is key to building public trust.

Regional Ripple Effects: How Arunachal’s Crisis Affects the Northeast

The implications of Arunachal Pradesh’s pharmacy crisis extend far beyond its borders. The Northeast region, comprising eight states, shares porous borders with Bhutan, Myanmar, and Bangladesh—all known transit points for counterfeit pharmaceuticals. A 2022 report by the Narcotics Control Bureau (NCB) identified the Moreh (Manipur)-Tamu (Myanmar) and Dimapur (Nagaland)-Chittagong (Bangladesh) corridors as major smuggling routes for fake medicines. Arunachal Pradesh, with its long international border in the east, is particularly vulnerable to cross-border infiltration.

Moreover, the region’s healthcare system is interconnected. Patients from Arunachal Pradesh often travel to Assam or West Bengal for specialized care, carrying prescriptions that may be filled by unregulated pharmacies on return. This creates a domino effect: poor drug quality in one state undermines treatment outcomes in another. The Northeast has the highest tuberculosis burden in India, with 85,000 new cases reported annually. The rise of multi-drug-resistant TB in the region has been linked, in part, to the use of counterfeit second-line antibiotics—many of which enter through unregulated supply chains.

In response, the Ministry of Health and Family Welfare has launched the “Northeast Pharmaceutical Security Initiative,” a multi-state task force that includes Arunachal Pradesh, Assam, and Manipur. The initiative focuses on joint raids, inter-state coordination, and the use of blockchain technology to track drug distribution. While still in its infancy, this collaborative model offers a blueprint for how India can address pharmaceutical crime across porous borders.

Case Studies: When Regulation Fails, Lives Are at Risk

To understand the human cost of weak enforcement, consider the case of Tawang district, where a 2023 outbreak of gastroenteritis was traced to contaminated oral rehydration salts (ORS) sold at a local pharmacy. The shop owner had procured the packets from an unlicensed distributor in Guwahati. By the time the DHS intervened, 14 children had been hospitalized with severe dehydration. Lab tests confirmed the presence of E. coli in the ORS packets—indicating fecal contamination during packaging or storage.

In another incident, a batch of counterfeit paracetamol tablets, manufactured in a clandestine unit in Nagaland, was seized in Itanagar. The tablets contained acetaminophen but were packaged to resemble a well-known brand. The counterfeit version lacked the active ingredient in the correct dosage, leading to inadequate fever control in children. Parents, unaware of the substitution, continued administering the medicine, resulting in prolonged illness and secondary infections.

These cases are not isolated. A 2023 audit by the Comptroller and Auditor General (CAG) of India revealed that 68% of medicine samples collected from Northeast pharmacies failed quality tests—compared to a national average of 22%. The most common violations included improper storage, expired drugs, and mislabeled packaging.

The Road Ahead: Strengthening Enforcement, Building Trust

For Arunachal Pradesh’s pharmacy licensing drive to succeed, it must evolve from a punitive exercise to a sustainable system of public health protection. This requires a three-pronged approach: strengthening regulatory capacity, empowering communities, and leveraging technology.

1. Strengthening Regulatory Capacity

The state currently has only 12 drug inspectors for over 1,200 licensed pharmacies—a ratio of 1:100. To improve oversight, the DHS must recruit and train more inspectors, with a focus on rural areas. Partnerships with the Indian Pharmacopoeia Commission (IPC) and National Accreditation Board for Testing and Calibration Laboratories (NABL) can help establish mobile drug testing labs that travel to remote districts. Additionally, the state government should consider offering incentives for licensed pharmacies that exceed compliance standards—such as tax breaks or priority access to government tenders.

2. Empowering Communities

Public awareness is the first line of defense against counterfeit drugs. The DHS has begun training school teachers, ASHA workers, and village heads to recognize signs of fake medicines—such as inconsistent packaging, misspelled labels, or unusually low prices. In West Siang district, a local NGO launched a “Medicine Safety Helpline,” where residents can report suspicious drugs via WhatsApp. Within six months, the helpline received 212 complaints, leading to the seizure of over 15,000 counterfeit tablets. This grassroots model demonstrates how community engagement can amplify enforcement efforts.

3. Leveraging Technology

Digital tools are transforming pharmaceutical regulation globally, and Arunachal Pradesh must catch up. The integration of AI-powered surveillance systems—such as those used by the U.S. Food and Drug Administration (FDA)—could help detect anomalies in drug distribution patterns. For example, sudden spikes in the sale of a specific antibiotic in a remote district could trigger an investigation. Additionally, the use of blockchain for drug pedigree tracking ensures that every medicine can be traced back to its manufacturer, making it nearly impossible to introduce counterfeit products into the supply chain.

Conclusion: A Model for India’s Peripheral States

The licensing drive in Arunachal Pradesh is more than a crackdown—it is a declaration that no citizen should have to choose between affordable medicine and safe medicine. In a state where the nearest hospital can be a day’s journey away, the integrity of every pill matters. But the lessons from Arunachal Pradesh extend far beyond its borders. They offer a roadmap for how India can protect its most vulnerable regions from the scourge of counterfeit drugs: through stronger enforcement, community vigilance, and technological innovation.

The road ahead is long. Counterfeiters adapt quickly, and regulatory systems must be agile. Yet, the early signs are encouraging. With increased funding from the National Health Mission and support from civil society, Arunachal Pradesh is poised to become a model for pharmaceutical security in India’s Northeast. The question is no longer whether the state can fix its pharmacy crisis—but how quickly it can do so before another life is lost to a preventable tragedy.